EP-0057 is under clinical development by Ellipses Pharma and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EP-0057’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EP-0057 overview
EP-0057 (NLG-207, CRLX-101) is under development for the treatment of solid tumors including epithelial ovarian cancer, peritoneal cancer, fallopian tube cancer, small-cell lung cancer, and metastatic castration-resistant prostate cancer (mCRPC). The drug candidate is administered intravenously. It acts by targeting hypoxia inducible factor 1 (HIF-1) alpha and topoisomerase I. It comprises the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer. The drug candidate is a poly-cyclodextrin-bis-cysteine-PEG3400-camptothecin-conjugate and it is developed based on cyclodextrin nanoparticle technology (CDP) (Cyclosert). It was also under development for the treatment of lymphoma, small cell lung cancer, non-small cell lung cancer, gastric cancer, esophageal cancer, adenocarcinoma of the gastroesophageal Junction, metastatic triple negative breast cancer, rectal cancer and metastatic renal cell carcinoma.
Ellipses Pharma overview
Ellipses Pharma is a drug development company focused on the advancement of innovative cancer treatments through the clinic. The company’s pipeline products include EP0042 is for the treatment of acute myeloid leukaemia (AML); EP0062 treats breast cancer; EP0031 targets Rearranged during transfection (RET) + solid tumours; EP0057 for ovarian and gastric cancer. Its services include clinical trials and clinical development. It markets its products under the brand Ellipses Pharma. Ellipses Pharma is headquartered in London, England, the UK.
For a complete picture of EP-0057’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
